Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers.
ECG
cardiac magnetic resonance
echocardiogram
sex
sudden cardiac death
Journal
Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365
Informations de publication
Date de publication:
04 08 2020
04 08 2020
Historique:
received:
02
04
2020
revised:
27
05
2020
accepted:
01
06
2020
entrez:
1
8
2020
pubmed:
1
8
2020
medline:
20
1
2021
Statut:
ppublish
Résumé
Predictive genetic screening of relatives of patients with hypertrophic cardiomyopathy (HCM) caused by sarcomere protein (SP) gene mutations is current standard of care, but there are few data on long-term outcomes in mutation carriers without HCM. The aim of this study was to determine the incidence of new HCM diagnosis in SP mutation carriers. This was a retrospective analysis of adult and pediatric SP mutation carriers identified during family screening who did not fulfill diagnostic criteria for HCM at first evaluation. The authors evaluated 285 individuals from 156 families (median age 14.2 years [interquartile range: 6.8 to 31.6 years], 141 [49.5%] male individuals); 145 (50.9%) underwent cardiac magnetic resonance (CMR). Frequency of causal genes was as follows: MYBPC3 n = 123 (43.2%), MYH7 n = 69 (24.2%), TNNI3 n = 39 (13.7%), TNNT2 n = 34 (11.9%), TPM1 n = 9 (3.2%), MYL2 n = 6 (2.1%), ACTC1 n = 1 (0.4%), multiple mutations n = 4 (1.4%). Median follow-up was 8.0 years (interquartile range: 4.0 to 13.3 years) and 86 (30.2%) patients developed HCM; 16 of 50 (32.0%) fulfilled diagnostic criteria on CMR but not echocardiography. Estimated HCM penetrance at 15 years of follow-up was 46% (95% confidence interval [CI]: 38% to 54%). In a multivariable model adjusted for age and stratified for CMR, independent predictors of HCM development were male sex (hazard ratio [HR]: 2.91; 95% CI: 1.82 to 4.65) and abnormal electrocardiogram (ECG) (HR: 4.02; 95% CI: 2.51 to 6.44); TNNI3 variants had the lowest risk (HR: 0.19; 95% CI: 0.07 to 0.55, compared to MYBPC3). Following a first negative screening, approximately 50% of SP mutation carriers develop HCM over 15 years of follow-up. Male sex and an abnormal ECG are associated with a higher risk of developing HCM. Regular CMR should be considered in long-term screening.
Sections du résumé
BACKGROUND
Predictive genetic screening of relatives of patients with hypertrophic cardiomyopathy (HCM) caused by sarcomere protein (SP) gene mutations is current standard of care, but there are few data on long-term outcomes in mutation carriers without HCM.
OBJECTIVES
The aim of this study was to determine the incidence of new HCM diagnosis in SP mutation carriers.
METHODS
This was a retrospective analysis of adult and pediatric SP mutation carriers identified during family screening who did not fulfill diagnostic criteria for HCM at first evaluation.
RESULTS
The authors evaluated 285 individuals from 156 families (median age 14.2 years [interquartile range: 6.8 to 31.6 years], 141 [49.5%] male individuals); 145 (50.9%) underwent cardiac magnetic resonance (CMR). Frequency of causal genes was as follows: MYBPC3 n = 123 (43.2%), MYH7 n = 69 (24.2%), TNNI3 n = 39 (13.7%), TNNT2 n = 34 (11.9%), TPM1 n = 9 (3.2%), MYL2 n = 6 (2.1%), ACTC1 n = 1 (0.4%), multiple mutations n = 4 (1.4%). Median follow-up was 8.0 years (interquartile range: 4.0 to 13.3 years) and 86 (30.2%) patients developed HCM; 16 of 50 (32.0%) fulfilled diagnostic criteria on CMR but not echocardiography. Estimated HCM penetrance at 15 years of follow-up was 46% (95% confidence interval [CI]: 38% to 54%). In a multivariable model adjusted for age and stratified for CMR, independent predictors of HCM development were male sex (hazard ratio [HR]: 2.91; 95% CI: 1.82 to 4.65) and abnormal electrocardiogram (ECG) (HR: 4.02; 95% CI: 2.51 to 6.44); TNNI3 variants had the lowest risk (HR: 0.19; 95% CI: 0.07 to 0.55, compared to MYBPC3).
CONCLUSIONS
Following a first negative screening, approximately 50% of SP mutation carriers develop HCM over 15 years of follow-up. Male sex and an abnormal ECG are associated with a higher risk of developing HCM. Regular CMR should be considered in long-term screening.
Identifiants
pubmed: 32731933
pii: S0735-1097(20)35559-5
doi: 10.1016/j.jacc.2020.06.011
pmc: PMC7397507
pii:
doi:
Substances chimiques
DNA
9007-49-2
Cardiac Myosins
EC 3.6.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
550-559Subventions
Organisme : British Heart Foundation
ID : FS/16/72/32270
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T005181/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T024062/1
Pays : United Kingdom
Organisme : Department of Health
ID : GOSH BRC
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Références
J Am Coll Cardiol. 2003 Sep 3;42(5):873-9
pubmed: 12957435
Eur Heart J. 2017 Dec 7;38(46):3434-3440
pubmed: 29020402
JAMA Cardiol. 2020 Jan 1;5(1):73-80
pubmed: 31774458
Int J Cardiol. 2011 Oct 20;152(2):258-9
pubmed: 21862152
J Card Fail. 2018 May;24(5):281-302
pubmed: 29567486
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Circulation. 2019 Jul 16;140(3):184-192
pubmed: 31006259
Circulation. 2013 Jan 1;127(1):48-54
pubmed: 23197161
Circulation. 2005 Aug 9;112(6):855-61
pubmed: 16087809
J Am Coll Cardiol. 2003 Jan 15;41(2):315-21
pubmed: 12535828
Eur Heart J Cardiovasc Imaging. 2019 Dec 1;20(12):1321-1331
pubmed: 31544926
Circulation. 2019 Feb 5;139(6):830-833
pubmed: 30715937
Circulation. 2003 Sep 2;108(9):1133-8
pubmed: 12925456
Circ Genom Precis Med. 2018 Apr;11(4):e001896
pubmed: 29661763
J Am Coll Cardiol. 2000 Dec;36(7):2212-8
pubmed: 11127463
Am J Cardiol. 2009 Sep 1;104(5):695-9
pubmed: 19699347
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
J Pediatr. 2017 Sep;188:91-95
pubmed: 28396031
PLoS One. 2014 Jul 21;9(7):e102969
pubmed: 25047602
Eur Heart J. 2014 Oct 14;35(39):2733-79
pubmed: 25173338
Heart. 2016 Nov 15;102(22):1805-1812
pubmed: 27590665
Eur Heart J. 2011 May;32(9):1161-70
pubmed: 21459882
J Am Coll Cardiol. 2011 Dec 13;58(25):e212-60
pubmed: 22075469
N Engl J Med. 2003 Jan 23;348(4):295-303
pubmed: 12540642